StreetInsider.com News Articles

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26585514.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26585514.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Callos Andrew

Mon, 01 Jun 2026 18:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26585509.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Callos Andrew

Mon, 01 Jun 2026 18:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26585509.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: PARSHALL B LYNNE

Mon, 01 Jun 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26585505.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: PARSHALL B LYNNE

Mon, 01 Jun 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26585505.html

Form 144 CYTOKINETICS INC Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26583914.html

Form 144 CYTOKINETICS INC Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26583914.html

Cytokinetics launches MYQORZO in Germany, first EU market

Mon, 01 Jun 2026 07:32:24 -0400

Cytokinetics (NASDAQ: CYTK) announced the commercial launch of MYQORZO (aficamten) in Germany for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. The drug launch represents the first European market availability following European Commission approval in February 2026.

MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy. The drug received approval based on results from the SEQUOIA-HCM Phase 3 clinical trial.

In the 24-week study, patients treated with aficamten showed improved exercise capacity compared to placebo. Peak oxygen uptake increased by 1.76 mL/kg/min from baseline in the treatment group versus

Cytokinetics launches MYQORZO in Germany, first EU market

Mon, 01 Jun 2026 07:32:24 -0400

In the 24-week study, patients treated with aficamten showed improved exercise capacity compared to placebo. Peak oxygen uptake increased by 1.76 mL/kg/min from baseline in the treatment group versus

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Mon, 01 Jun 2026 07:30:00 -0400

European Launch Follows Strong U.S. Start

SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.

Marking the first of several planned European

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Mon, 01 Jun 2026 07:30:00 -0400

European Launch Follows Strong U.S. Start

Marking the first of several planned European

Form 4 CYTOKINETICS INC For: May 27 Filed by: Blum Robert I

Thu, 28 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260528/26567737.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Blum Robert I

Thu, 28 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260528/26567737.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Bhanji Muna

Wed, 27 May 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26559572.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Bhanji Muna

Wed, 27 May 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26559572.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Daly James M

Wed, 27 May 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26559571.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Daly James M

Wed, 27 May 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26559571.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Harrington Robert Arthur

Wed, 27 May 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260527/26559569.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Harrington Robert Arthur

Wed, 27 May 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260527/26559569.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: HENDERSON JOHN T

Wed, 27 May 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26559568.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: HENDERSON JOHN T

Wed, 27 May 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26559568.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Kaye Edward M. MD

Wed, 27 May 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26559566.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: Kaye Edward M. MD

Wed, 27 May 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26559566.html

Form 4 CYTOKINETICS INC For: May 27 Filed by: PARSHALL B LYNNE

Wed, 27 May 2026 19:10:00 -0400

si-local-file:///var/storage/secattach/20260527/26559565.html